Novel Peptides in Resistant Human Hypertension

Trial Profile

Novel Peptides in Resistant Human Hypertension

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Nesiritide (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2016 Status changed from suspended to discontinued.
    • 08 Nov 2013 Planned end date changed from 1 Jan 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top